| Subject: | FDA Announces Recall of Fentanyl Transdermal System CII Patches |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 20 Feb 2008 - 05:00 pm |
| Audience: Pain management specialists, risk managers, other healthcare professionals, patientsThe FDA and Actavis Inc. have announced a nationwide recall of certain lots of Fentanyl transdermal system CII Patches sold in the United States and labeled with an Abrika or Actavis label. The product may have a fold-over defect that can cause the patch to leak and expose patients or caregivers directly to the fentanyl gel. Exposure to fentanyl gel may lead to serious adverse events, including... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
